Nusinersen (Spinraza)


Original post, click here

Generic Name: Nusinersen

Brand Name: Spinraza

Manufacturer: Biogen Canada Inc.

Indications: Spinal Muscular Atrophy

Manufacturer Requested Reimbursement Criteria1:

​That nusinersen be reimbursed for the treatment of 5q Spinal Muscular Atrophy (SMA) [including presymptomatic, Types I, II and III patients].

Submission Type: Resubmission

Project Status: Pending

Call For Patient Input: June 22, 2018

Patient Input Closed: August 14, 2018

Anticipated Date: July 23, 2018

Biosimilar: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Submit Feedback

Tags

genetics, nervous system, pediatrics, musculoskeletal